Shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) saw unusually-strong trading volume on Friday . Approximately 295,341 shares changed hands during trading, a decline of 1% from the previous session’s volume of 299,231 shares.The stock last traded at $10.25 and had previously closed at $10.26.

Several research firms have recently weighed in on AIMT. Piper Jaffray Cos. reiterated an “overweight” rating and set a $38.00 price objective on shares of Aimmune Therapeutics in a research report on Wednesday, June 29th. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Friday, May 20th. Bank of America Corp. reiterated a “buy” rating on shares of Aimmune Therapeutics in a research report on Monday, May 16th. Finally, Wedbush reiterated an “outperform” rating and set a $42.00 price objective on shares of Aimmune Therapeutics in a research report on Monday, June 13th. Five investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of $33.40.

The company has a 50 day moving average price of $13.06 and a 200-day moving average price of $14.66. The company’s market capitalization is $443.17 million.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Monday, May 16th. The company reported ($0.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.03. On average, equities analysts predict that Aimmune Therapeutics Inc. will post ($1.70) EPS for the current fiscal year.

In other news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 31st. The shares were sold at an average price of $15.23, for a total value of $3,655,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

A number of large investors have recently bought and sold shares of AIMT. Alps Advisors Inc. purchased a new stake in Aimmune Therapeutics during the fourth quarter worth approximately $1,027,000. Aisling Capital LLC raised its stake in Aimmune Therapeutics by 6.0% in the fourth quarter. Aisling Capital LLC now owns 2,990,000 shares of the company’s stock worth $55,166,000 after buying an additional 170,000 shares in the last quarter. Finally, TLP Group LLC purchased a new stake in Aimmune Therapeutics during the fourth quarter worth approximately $51,314,000.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.